eli lilly oral semaglutide Lilly's GLP-1RA hits endpoints, but trails Novo's Wegovy in weight loss FDA Grants Speedy Approval to

Alcohol consumption can affect glycemic control, and the combination of GLP-1 therapy with alcohol might increase hypoglycemia risk, particularly in patients taking concomitant insulin or sulfonylureas

This is the most frequently reported effect and is inherent to GHRP-6's mechanism Mild water retention and peripheral edema, particularly during the first 2 to 4 weeks Transient flushing, warmth, or dizziness immediately post-injection Injection site reactions (redness, minor swelling) Less Common: Tingling or numbness in the extremities (hands and feet), related to GH-mediated fluid shifts Head rush or lightheadedness shortly after administration Drowsiness, particularly with evening doses Dose-Dependent (above saturation dose): Elevated cortisol via ACTH stimulation

doi: 10.1038/ijo.2013.162 7

Our special reports key findings include the following: Labeled indications for GLP-1 RAs (i.e., patients with body mass index [BMI] 30 kg/m2 or 27 kg/m2 with obesity-related comorbidities) follow a longstanding consensus established by the National Heart, Lung, and Blood Institutes 1998 guidelines on obesity management

Even users who normally tolerate alcohol well often find even small amounts trigger significant discomfort while on this medication

Mohammed GF, Al-Dhubaibi MS, Bahaj SS, Mohammed RM